Silodosin

Drug Profile

Silodosin

Alternative Names: KAD 3213; KMD-3213; KSO-0400; Rapaflo; Silodyx; Thrupas; Urief; Urief OD; Urorec

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Actavis; Allergan; Almirall S.A.; Daiichi Sankyo Company; Eisai Co Ltd; JW Pharmaceutical; Kissei Pharmaceutical; Pharmaplan; Recordati; Synmosa Biopharma; Zambon France
  • Class Benzamides; Indoles; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase II Urinary calculi
  • Clinical Phase Unknown Nocturia
  • No development reported Prostatitis

Most Recent Events

  • 18 Nov 2016 Preregistration is ongoing for Benign prostatic hyperplasia in Sri Lanka (Kissei pipeline, November 2016)
  • 01 Nov 2016 Launched for Benign prostatic hyperplasia in Cambodia (PO) (Kissei pipeline, November 2016)
  • 31 Mar 2016 Registered for Benign prostatic hyperplasia in Cambodia (PO) (Kissei Annual Report, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top